AstraZeneca Farce on the Withdrawal of Covid Vaccine Unsold in India and EU for 2 years… But still authorized in UK
by Carlo Domenico Cristofori
There are NO-VAX journalists who claim victory at the first farce news launched by mainstream newspapers and there are transparent global journalism sites that instead question the meaning of AstraZeneca’s announcement on the withdrawal of the authorization for the emergency use of the serum anti-Covid mDNA Vaxzevria gene in the European Union.
Here, in fact, it had already disappeared from the market on January 1, 2022, i.e. for two years, I say that the EU Commission had interrupted its purchase due to the serious adverse reactions that had led to its definitive suspension in many EU countries but not in Italy, as it is based on a monkey adenoviral vector developed by the Science Park of Pomezia (Rome) financed by the PD of the governor of Lazio Nicola Zingaretti and therefore defended to the point of lies by his party mate Roberto Speranza, former Minister of Health.
«AstraZeneca said today that it has started the worldwide recall of its Covid-19 vaccine. The international media reported it. The pharmaceutical company added that it will proceed with the withdrawal of the marketing authorizations for Vaxzevria in Europe» writes RAI News, the website of the Italian national TV, revealing a double falsehood.
First of all because the AstraZeneca vaccine was widespread in a few countries around the world, having never been approved in the USA or Canada, for example.
«Because of manufacturing and data submission issues, the FDA never approved Vaxzevria and in November 2022, the company abandoned its efforts to gain approval of the shot in the U.S» recalls the specialized site FiercePharma, reporting the withdrawal which occurred only in the EU.
Still no news on the recall in the UK
Secondly, because there is no trace of the withdrawal throughout EUROPE, since the United Kingdom, until proven otherwise, is also part of the Old West, which on its official website refers only to an update dated 22 November 2023, and there are no news on the impending withdrawal in the UK on the Medicines and Healthcare products Regulatory Agency website.
Not only. India is also wondering about the reason for an announcement of a withdrawal of the vaccine which was no longer purchased by the former British colony since December 2021…
On Tuesday, the EMA said it had accepted a request from AZ and withdrawn (PDF) the company’s marketing authorization for its COVID-19 shot Vaxzevria.
The vaccine, which was co-developed by Oxford University, was the world’s third most-used COVID shot, with more than 3 billion doses supplied. The company reportedsales of $4 billion from the shot in 2021 and $1.8 billion in 2022.
“As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company said in an emailed statement. “This has led to a decline in demand for Vaxzervria, which is no longer being manufactured or supplied.”
The Oxford-AstraZeneca Covid vaccine is being withdrawn worldwide, months after the pharmaceutical giant admitted for the first time in court documents that it can cause a rare and dangerous side effect.
The vaccine can no longer be used in the European Union after the company voluntarily withdrew its “marketing authorisation”. The application to withdraw the vaccine was made on March 5 and came into effect on Tuesday, The Telegraph reported..
Vaxzevria has come under intense scrutiny in recent months over a very rare side effect, which causes blood clots and low blood platelet counts. AstraZeneca admitted in court documents lodged with the High Court in February that the vaccine “can, in very rare cases, cause TTS”,
AstraZeneca Taken to British Court for as many as 80 Damages Claims on “Defective” Covid Jab
TTS – which stands for Thrombosis with Thrombocytopenia Syndrome – has been linked to at least 81 deaths in the UK as well as hundreds of serious injuries. AstraZeneca is being sued by more than 50 alleged victims and grieving relatives in a High Court case.
«Similar applications will be made in the coming months in the UK and in other countries that had approved the vaccine, known as Vaxzevria» The Telegraph added.
It remains a commercial, health and political mystery as to why AstraZeneca asked for withdrawal in the EU, where it had no longer been sold for 2 years, and not in the UK where it continues to be on the market despite the undesirable effects recognized by the Government:
- Hypersensitivity including anaphylaxis
- Concurrent illness
- Coagulation disorders
- Thrombosis with thrombocytopenia syndrome: Thrombosis with thrombocytopenia syndrome (TTS), in some cases accompanied by bleeding, has been observed very rarely following vaccination with Vaxzevria. This includes severe cases presenting as venous thrombosis, including unusual sites such as cerebral venous sinus thrombosis, splanchnic vein thrombosis, as well as arterial thrombosis, concomitant with thrombocytopenia. TTS requires specialised clinical management. Healthcare professionals should consult applicable guidance and/or consult specialists (e.g., haematologists, specialists in coagulation) to diagnose and treat this condition.
- Thrombocytopenia: Cases of thrombocytopenia, including immune thrombocytopenia (ITP), have been reported after receiving Vaxzevria, typically within the first four weeks after vaccination. Very rarely, these presented with very low platelet levels (<20,000 per µL) and/or were associated with bleeding. Cases with fatal outcome have been reported.
- Risk of bleeding with intramuscular administration
- Capillary leak syndrome
- Neurological events: Guillain-Barré Syndrome (GBS) has been reported very rarely following vaccination with Vaxzevria. Healthcare professionals should be alert of GBS signs and symptoms to ensure correct diagnosis, in order to initiate adequate supportive care and treatment, and to rule out other causes.
- Risk of very rare events after a booster dose
Italian Girl Killed by Vaccine! Coroner Claimed Adverse Effect by AstraZeneca
Even in India Vaxzevria production has been stopped since 2 years
«The company has maintained that the withdrawal is not linked to the court case or its admission of TTS side effects, but rather due to commercial reasons and a decline in demand» India Today wrote.
“We are incredibly proud of the role Vaxzevria played in ending the global pandemic. According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over three billion doses were supplied globally. Our efforts have been recognised by governments around the world, and are widely regarded as being a critical component of ending the global pandemic,” AstraZeneca told India Today.
The vaccine, known as Covishield in India and other low- and middle-income countries, was developed by AstraZeneca and Oxford University in response to the coronavirus pandemic in 2020.
«While AstraZeneca has voluntarily withdrawn the marketing authorization for Vaxzevria in the European Union, similar applications are expected to be made in other countries, including India, where the vaccine was manufactured and distributed by the Serum Institute of India (SII) under a license» India Today added.
However, the decision to withdraw the vaccine should not be seen as alarming.
Sources within the Health Ministry told India Today that the Indian government has not purchased any Covid-19 vaccines in the last two years, and there is no indication of purchasing any more vaccines in the near future.
Additionally, SII has a stock of 250 million doses of Covishield at its Pune facility, which could be used for any future eventuality.
Meanwhile, Serum Institute of India said that the firm had stopped the manufacturing and supply of additional doses of Covishield since December 2021.
“With India achieving high vaccination rates in 2021 and 2022, coupled with the emergence of new mutant variant strains, the demand for previous vaccines diminished significantly. Consequently, since December 2021, we have stopped the manufacturing and supply of additional doses of Covishield,” the Serum Institute spokesperson said on Wednesday.
AstraZeneca: maxi-investment for the next pandemic
«Today (6 March) pharmaceutical firm AstraZeneca has outlined plans to invest £650 million in the UK – helping boost the UK’s world leading Life Sciences sector and grow the economy. This significant investment will enhance public health protection and pandemic preparedness» this is what we read on the official Gov.UK-MHRA website.
AstraZeneca intends to invest £450 million at their manufacturing site in Speke, Liverpool for the research, development, and manufacture of vaccines – building on the site’s current role in supplying the world leading childhood vaccination programme. The new facility will be designed and built to be operationally net zero with power supplied from renewable energy sources.
In a further boost for the UK’s resilience for future pandemics and global health threats, AstraZeneca and the UK Health Security Agency (UKHSA) plan to work in partnership to advance science for developing and evaluating vaccines – using technology from both AstraZeneca’s manufacturing site in Speke and the UKHSA’s Vaccine Development Evaluation Centre (VDEC) at their Porton Down site.
AstraZeneca will also expand its presence at Europe’s largest life sciences cluster in Cambridge with £200 million in investment. The facility will house around 1,000 employees and will be adjacent to its £1.1 billion global R&D Discovery Centre (DISC), which already hosts 2,300 researchers and scientists. These jobs will provide opportunities for people looking to get the skills they need to succeed in life and – with cuts to National Insurance – enjoy more money in their pocket as a result of their hard work.
Dr Isabel Oliver, Chief Scientific Officer at UKHSA, said:
«This investment will bolster the development of the UK’s vaccine capabilities and life sciences sector – critical components of the country’s resilience to future health threats».
«UKHSA majors on researching and developing new ways to strengthen the country’s defences against all health hazards – including future pandemics – and works routinely with a range of commercial and academic partners. We are looking forward to working with AstraZeneca to collectively protect the population’s health».
Carlo Domenico Cristofori
© COPYRIGHT GOSPA NEWS
prohibition of reproduction without authorization
follow Fabio Carisio Gospa News director on Twitter
follow Gospa News on Telegram
MAIN SOURCES
GOV.UK – AstraZeneca plans £650 million investment in UK
GOSPA NEWS – WUHAN-GATES DOSSIER
“White House’s Pressure on Meta to Censor SARS-Cov-2 Lab Leak Theory”. Zuckerberg email disclosed
https://www.gospanews.net/en/2024/05/03/wuhan-gates-76-the-criminal-partner-of-fauci-gates-lied-to-us-congress-on-sars-cov-2-bioweapon/
